URINARY TRACT INFECTION THERAPEUTIC MARKET ANALYSIS

Market Challenges And Opportunities

Global Urinary Tract Infection Therapeutic Market Drivers:

High prevalence of urinary tract infection across the globe is expected to augment the growth of the global urinary tract infection therapeutic market over the forecast period. For instance, Urinary tract infection is the infection of bladder, urethra, ureter, and kidneys and occurs due to colonization of microbial pathogen in the bladder or the kidneys. According to the National Center for Biotechnology Information (NCBI), UTIs are among the most common bacterial infections, affecting 150 million people worldwide each year. This in turn expected to increase demand for urinary tract infection therapeutics worldwide.

Increasing prevalence of diabetes and increasing geriatric population is expected to propel the growth of the global urinary tract infection therapeutic market during the forecast period. For instance, urinary tract infections can be a particular problem for people with diabetes as sugar in the urine makes for a fertile breeding ground for bacteria. Diabetes raises a person's risk for urinary tract infections. According to the World Health Organization (WHO), more than 422 million people worldwide have diabetes, majority of them living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year.

Global Urinary Tract Infection Therapeutic Market Opportunities:

Increase in focus on the development of novel drugs is expected to provide significant growth opportunities for players in the global urinary tract infection therapeutic market. For instance, with the increase in prevalence of UTIs, the demand for UTI therapeutics is also increasing. In September 2020, CARB-X planned to invest over US$ 7.51 million in GlaxoSmithKline, with an aim to help develop GSK3882347, an orally bioavailable small molecule drug, for both the treatment and prevention of recurrent UTIs caused by E. coli bacteria.

Increase in research and development is expected to provide lucrative growth opportunities for players in the urinary tract infection therapeutic market. For instance, R&D in UTI treatment is expected to offer lucrative growth opportunities for players in the market. In August 2020, researchers at the California Polytechnic State University developed a new class of antibiotics for urinary tract infections (UTIs), which targets bacterial iron acquisition, at the American Chemical Society (ACS) Fall 2020 Virtual Meeting & Expo.

Global Urinary Tract Infection Therapeutic Market Restraints:

Adverse effects associated with the use of UTI medication are expected to hinder growth of the global urinary tract infection therapeutic market. For instance, side effects associated with UTI therapeutics like fluoroquinolones, such as variations in blood sugar levels and central nervous system problems such as insomnia, seizures, and anxiety may impede the growth of the urinary tract infection therapeutic market over the forecast period. More serious side effects can include antibiotic-resistant infections or C. diff infection, which causes diarrhea that can lead to severe colon damage and death.

Lack of awareness among people, in developing and underdeveloped countries, is expected to hamper growth of the global urinary tract infection therapeutic market. For instance, urinary tract infections are the second most common type of infection in the body. The infections can affect several parts of the urinary tract. UTIs are very common, if left untreated, bacteria-laden urine can travel to the kidneys and cause serious, even life-threatening complications. Thus, it is important to be aware of urinary tract infection and its therapeutics.